SAL073

SAL073 is an investigational small molecule agonist of the Glucagon-like peptide 1 receptor (GLP-1R), currently in preclinical development by Shenzhen Salubris Pharmaceuticals. It is being evaluated for the treatment of metabolic disorders, specifically type 2 diabetes mellitus and obesity. Unlike traditional GLP-1 therapies which are typically peptides requiring subcutaneous injection, SAL073 is a small molecule designed for oral administration. By binding to and activating the GLP-1 receptor, it enhances glucose-dependent insulin secretion, suppresses glucagon secretion, and promotes satiety, thereby improving blood sugar levels and facilitating weight loss.